Global Vaccine Safety

Acting out a Vaccine Safety Crisis – A unique training in Tanzania, March 2016

At request of the Ministry of Health, Community Development, Gender, Elderly and Children, United Republic of Tanzania, WHO organized an innovative Adverse Event Following Immunization (AEFI) field investigation and communication simulation training in Bagamoyo, from 14 to 18 March 2016. Participants included officers from the Tanzania Food and Drugs Authority (TFDA), immunization programme (IVD), members of the national AEFI Committee, regional immunization and vaccine officers and experts from partner organizations in Tanzania.

Revised Core Variables and Reporting form for adverse events following immunization (AEFI)

To encourage countries to report AEFI with essential information, the Global Advisory Committee on Vaccine Safety (GACVS) proposed in June 2012 a set of simple and vaccine-specific minimum 22 AEFI records (core variables). An AEFI reporting form incorporating these core variables was subsequently developed and used by several member states. GACVS recently reviewed feedback received from countries and recommended the inclusion of three additional variables. This revised set of variables should enhance the quality of data collected and enable national programme managers in Member States to better monitor vaccine safety. A revised AEFI reporting form incorporating these changes has been developed by WHO.

GACVS highlight of December 2015 meeting

The Global Advisory Committee on Vaccine Safety (GACVS) held its 33rd meeting in Geneva, Switzerland, on 2–3 December 2015. The Committee examined the clinical and population characteristics of cluster immunization anxiety-related reactions and the detection of vaccine safety signals from spontaneous reporting databases. It also reviewed vaccine-specific safety issues concerning RTS,S malaria vaccine, safety of human papillomavirus (HPV) vaccines, pandemic influenza vaccine and narcolepsy, and the safety profile of smallpox vaccines. GACVS findings and recommendations were published in the WHO Weekly Epidemiological Record on 22 January 2016.

Report on the Fourth Global Vaccine Safety Initiative Meeting

The Fourth Global Vaccine Safety Initiative meeting took place in Evian, France on 14-15 October 2015. The Global Vaccine Safety Initiative (GVSI) is the implementation mechanism for the Global Vaccine Safety Blueprint, which is the WHO strategy to optimize the safety of vaccines in all countries through effective use of pharmacovigilance principles and methods.

During two days, immunization programme managers and national regulatory authorities pharmacovigilance staff from more than thirty countries gathered with representatives from UN agencies, academic institutions, pharmaceutical companies umbrella organizations, partner and funding agencies.

The overall objective of the meeting was for Member States and partners to interact and exchange information on progress with implementation of national and global vaccine pharmacovigilance activities, share new ideas, innovations, explore new frontiers in vaccine safety, build partnerships and collaborations and define plans for further development.

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



Looking for reliable information on vaccine safety?

Contact us

Global Vaccine Safety
World Health Organization
Switzerland
E-mail: gvsi@who.int